Study drug ADX-038 in healthy people and PNH patients
Treatments studied
Part of Blood & lymphatic clinical trials.
This early-stage study tests how safe and tolerable ADX-038 is, and how the body processes it, in healthy volunteers and in people with paroxysmal nocturnal hemoglobinuria (PNH). It may help researchers understand whether the drug works safely for PNH patients and identify the right dosing.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be between 18 and 55 years old (for the healthy-volunteer part)
- For PNH participation: you must have confirmed PNH with documented clone size
- For PNH participation: your hemoglobin must be below 12 g/dL
- Be up to date on meningococcal, pneumococcal, and Hib vaccines or agree to get them
- No recent infections close to the study start date (timing depends on which part you join)
- You must not have certain major health risks (like immune system problems, recent major surgery, or severe allergy history)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests an oral medication (MY008211A) designed to reduce red blood cell destruction in people with paroxysmal nocturnal hemoglobinuria (PNH). The trial aims to see if the drug is safe and effective in improving anemia and lowering markers of disease activity.
This study tests an investigational oral medication called TUL321 in healthy volunteers to see if it is safe and how the body handles it. It may help understand the drug's effects and is an early step in developing a new treatment.
This trial tests an experimental RNA drug (ALN-CFB) for people with PNH who still have low red blood cell counts despite taking a C5 inhibitor. The drug aims to block a protein (complement factor B) to improve anemia.
This trial tests a new investigational drug called CMS-D017 in healthy volunteers. Researchers will give single and multiple doses to see how the body processes it and if it's safe. You could help find an important new treatment.
This study checks the long-term safety of the drug MY008211A for people with paroxysmal nocturnal hemoglobinuria (PNH). It is only for those who already took the drug in an earlier study and had benefit, and who have had specific vaccines.
This study tests a new medicine called VSA012 for people with paroxysmal nocturnal hemoglobinuria (PNH), a rare blood disease. The goal is to see if VSA012 can help manage symptoms like fatigue and low blood counts better than the current standard treatment.
Hear when a new Paroxysmal Nocturnal Hemoglobinuria (PNH) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.